Stepping foot into a successful partnership to support your viral vector therapy through commercialization

Abstract

<p class="p2"><span class="s1"><span class="Apple-converted-space">&nbsp;</span></span><span class="s2"><b>Charlotte Barker, </b></span>Editor, <span class="s2"><i>Cell and Gene Therapy Insights</i></span>, <span class="s2"><b>speaks to Minh Hong, </b></span>Head of Commercial, Viral Gene Therapy, Merck, <span class="s2"><b>and Marc Gaal, </b></span>Director, Program Management at the Life Sciences Business Sector, Merck<span class="Apple-converted-space">&nbsp;</span> <div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Minh Hong copy.png" data-image="1"></div><div class="author-det"> <b>Minh Hong</b> leads the commercial team for Viral Gene Therapy contract manufacturing services within the Life Sciences Business Sector of Merck. He is responsible for account management, business development, and out-licensing activities of innovative viral vector manufacturing tools. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/MAG Profile pic small - Copy copy.jpg" data-image="1"></div><div class="author-det"> <b>Marc Gaal</b> heads Merck’s Commercial Project Management Office and is responsible for contract administration and project management of customer programs throughout the entire life cycle of the program. </div></div></div>